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The introduction of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection has allowed dramatic
reductions in plasma virus levels to below the limit of detection in many patients. However, latently infected CD41 memory
T lymphocytes persist as an important reservoir for the virus in the presence of this aggressive therapy and represent a
major barrier to HIV-1 eradication with HAART. The mechanism through which the latent compartment is formed has not yet
been established. It may involve actively proliferating CD41 T-cell intermediates that are infected with HIV-1 and revert back
to a resting state, carrying integrated provirus at some low frequency. The HIV-1 accessory protein Vpr, which mediates G2
cell cycle arrest in host cells, may interfere with the formation of the latently infected T cells by preventing them from exiting
the cell cycle to return to a resting state. To investigate the role of the Vpr in the formation of latently infected memory T cells,
we cloned and characterized vpr genes from viruses in the latent reservoir. Both sequence analysis and functional assays
demonstrated that the vpr gene products of the viruses isolated from the latent pool did not differ significantly from those
of a functional Vpr (NL4-3). These results indicate that the generation of resting G0 memory T lymphocytes that carry latent
HIV-1 provirus occurs despite the G2 arrest function of the vpr gene product. © 2000 Academic Press
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aINTRODUCTION
Advances in antiretroviral therapy, particularly the in-
troduction of highly active antiretroviral therapy (HAART),
allow control of viral replication in patients with HIV-1
infection. These regimens, which consist of combina-
tions of reverse transcriptase and protease inhibitors,
successfully reduce plasma HIV-1 RNA levels to below
the limit of detection of current assays in many patients
(Gulick et al., 1997; Hammer et al., 1997; Perelson et al.,
1997). However, it now appears that there is a low level
of continued virus production in most patients on HAART
(Dornadula et al., 1999; Furtaldo et al., 1999; Sharkey et
al., 2000; Zhang et al., 1999). In addition, HIV-1 persists in
stable reservoirs in successfully treated patients whose
plasma virus levels have fallen to undetectable levels
(Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997).
The major viral reservoir for which long-term persistence
was previously demonstrated consists of latently in-
fected resting CD41 T lymphocytes (Chun et al., 1997;
inzi et al., 1997, 1999; Perelson et al., 1997; Persaud et
l., 2000; Wong et al., 1997). These latently infected CD41
T lymphocytes have stably integrated provirus (Chun et
al., 1995, 1997), but show no active virus production until
they are activated in vitro (Chun et al., 1995). Latent
1 To whom correspondence and reprint requests should be ad-
ressed at Johns Hopkins University School of Medicine, Department
f Medicine, 1049 Ross Building, 720 Rutland Avenue, Baltimore, MD
1205. Fax: (410) 955-0964. E-mail: rsilicia@welch.jhu.edu.227infection is established during primary infection, and
establishment is not blocked by early antiretroviral treat-
ment (Chun et al., 1998; Finzi et al., 1997, 1999).
Given the fact that this latent reservoir represents a
major barrier to virus eradication in patients on HAART, it
is important to study the mechanism through which the
latent infection is established. Latent HIV-1 is found
mainly in resting CD41 T cells from the memory subset
Chun et al., 1995; Pierson et al., 2000), and the estab-
ishment of HIV-1 latency most likely occurs during the
eneration of memory T cells. It is generally believed that
emory T cells are produced when a small portion of the
ctivated T cells that respond to a particular antigen
evert to a resting state and survive as memory cells
apable of rapid activation upon reencountering the an-
igen. Latency may thus be established through a mech-
nism in which activated HIV-1-infected CD41 T cells
evert to a resting G0 state, carrying an integrated provi-
us that becomes transcriptionally silent in the resting
ell. Alternatively, latency may be established through
irect infection of resting memory T cells. However, the
xact mechanism through which the latently infected
esting T lymphocytes are generated has not yet been
stablished.
The HIV-1 accessory gene product viral protein R (Vpr)
nterferes with cell cycle progression, and causes a G2
arrest in infected host cells (Jowett et al., 1995; Rogel et
l., 1995). Vpr is a virion-associated 14-kDa protein
hich, in addition to perturbing the cell cycle, also plays
role in nuclear import of the preintegration complex0042-6822/00 $35.00
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228 SHEN ET AL.(PIC) in nondividing cells (Heinzinger et al., 1994) such as
terminally differentiated macrophages. Vpr may also be
involved in the induction of apoptosis in infected host T
cells that have undergone cell cycle arrested at G2
(Stewart et al., 1997).
The discovery that Vpr arrests host cells at G2 raised
he question of how infected T cells could escape G2
arrest and revert to a resting G0 state to form the latently
infected memory cell compartment. One hypothesis is
that only viruses containing mutant forms of the vpr gene
could establish latency. This hypothesis is based on the
observations that the vpr gene prevents cell proliferation
during chronic infection of T-cell lines and thus they
typically have inactivating vpr mutations (Planelles et al.,
1995; Rogel et al., 1995). To assess the functional status
of Vpr in latent virus, we cloned vpr genes from viral
isolates obtained from the latent reservoir of patients
who were successfully being treated with HAART. Both
sequence data and the functional studies demonstrated
that the vpr genes from latent HIV-1 did not have muta-
tions that render them nonfunctional. These results indi-
cate that the generation of resting G0 memory T lympho-
ytes that carry latent HIV-1 provirus occurs despite the
2 arrest function of the vpr gene product.
RESULTS
equence analysis of vpr genes from viruses
btained from latently infected cells
Vpr genes from viruses in the latent reservoir were
tudied in four patients who had undetectable levels of
lasma virus as a result of long-term HAART. Previous
tudies showed that, in such patients, HIV-1 persists in
ntegrated form in resting CD41 T cells (Finzi et al., 1997;
Chun et al., 1997; Perelson et al., 1997; Persaud et al.,
000; Wong et al., 1997). Viruses were isolated by stim-
lation of highly purified resting CD41 T cells under
imiting dilution conditions (Finzi et al., 1997). These vi-
uses represent replication-competent biological clones
erived from the latent reservoir. The isolates were used
o infect CD41 lymphoblasts in short-term cultures, and
the vpr genes were amplified by PCR using genomic
DNA from infected cells as a template. PCR products
were cloned and sequenced. To look for mutations that
render vpr nonfunctional, sequences of these clones
were compared with the HIV-1 clade B consensus se-
quence and that of the reference strain HIV-1 NL4-3
(which is known to have a functional vpr gene) (Fig. 1).
The sequences all contained open vpr reading frames
with no insertions or deletions that would affect the
reading frame. Each of the patient sequences differed
both from the others and from the reference sequences
as a result of distributed single nucleotide substitutions.
Each of these substitutions was previously observed in
at least one naturally occurring HIV-1 isolate. Inactivating
mutations demonstrated by mutagenesis studies, e.g.,
mutations at residues A30, R73, or R80 (Di Marzio et al.,1995; Mahalingam et al., 1997), were not observed. Taken
together, these data suggest that latent HIV-1 does not
contain previously observed inactivating mutations.
Vpr gene products from patient isolates were
functional in causing G2 arrest
To determine whether the vpr gene products from the
atient isolates were functional in inducing G2 cell cycle
arrest, we carried out high-efficiency cotransfections of
293T cells with constructs containing vpr genes from
patient isolates along with a vector expressing GFP. Flow
cytometry was performed to determine transfection effi-
ciency, as indicated by GFP expression, while cell cycle
arrest was measured by DNA content. A representative
experiment is shown in Fig. 2. Transfection efficiencies
were typically very high (Fig. 2A). They ranged from 70%
to 95% in different experiments but were consistent
among all samples within each experiment. In some
experiments, GFP-positive cells were sorted to 99% pu-
rity before cell cycle analysis, but cell sorting did not
significantly affect the ratio of cells in G2 vs cells in G1
(data not shown). After analysis of transfection efficiency,
the transfected cells were subject to PI staining to detect
DNA content. In Fig. 2B, the cells chemically arrested at
G2 by nicodazol as a positive control showed a high
proportion of cells with 2N DNA content. Figure 2C
shows DNA content profile of cells transfected with only
the pCI vector, and only a small fraction of cells in G2
were seen. A construct carrying a nonfunctional vpr from
the HXB2 isolate (Mahalingam et al., 1997) typically in-
duced only a background level of G2 arrest (Fig. 2D). A
ontrol construct carrying a functional vpr gene from the
eference NL4-3 isolate induced a modest but significant
evel of G2 arrest in transfected cells (Fig. 2E). FACS
rofiles of all the patient samples looked very similar to
hat of the wild-type Vpr, in that there were modest but
ignificant increases in the number of cells at G2 (Fig.
F). The ratios of cells in G2 1 M vs those in G1 1 G0
were calculated by dividing the percentage of cells in G2
1 M by that in G1 1 G0, indicated on top of the panels in
ig. 2. The ratio was typically 1.5-fold greater in cells
ransfected with wild-type vpr than with nonfunctional vpr
FIG. 1. Alignment of vpr sequences from patient isolates along with
the clade B-US vpr consensus sequence and wild-type vpr from the
eference HIV-1 NL4-3.
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229HIV-1 LATENCY NOT REQUIRING Vpr INACTIVATION(0.58 in wild-type; 0.38 in nonfunctional vpr). These vpr
gene products from the patient isolates had G21M :
11G0 ratios very close to that of the wild type.
Such functional assays were repeated multiple times
and three data points were collected for each patient
sample as well as the controls. The G21M : G11G0
ratios of the functional Vpr NL4-3 were used as a stan-
dard for vpr-induced cell cycle arrest (set to be 100%
arrest) in each experiment and all patient samples and
other controls were expressed as a percentage of arrest
seen in NL4-3. An average of the three data points is
shown in Fig. 3 with standard deviations. ANOVA and
Tukey–Kramer multiple comparison tests were per-
formed to determine the statistical significance of the
arrest. The results showed that there is no statistically
significant difference between the amount of G2 arrest
induced by wild-type Vpr (NL4-3) and the Vpr from patient
isolates (P , 0.05). This level of arrest was highly sig-
nificant (P , 0.05) compared to the much smaller G21M :
G11G0 ratios seen in cells transfected with the nonfunc-
tional Vpr (HXB-2) and pCI alone. Thus the patient vpr
genes were functionally equivalent to those of the wild
type in inducing cell cycle arrest.
FIG. 2. Effect of vpr gene products from latent viruses on cell cycle
ransfection of 293T cells, which were cotransfected with a vector con
8 h after transfection, the cells were analyzed by flow cytometry f
epresentative transfected sample is shown in the dark line. Seventy p
evel. Total cells (1 3 104) were analyzed for each sample. (B) 293T ce
PI staining. The ratio of cells in G2 1 M vs those in G1 1 G0 were calc
93T cells transfected with the vector pCI alone. (D) 293T cells transfec
ith pCI-NL4-3 expressing a wild-type vpr. (F) 293T cells transfected wTo determine whether the partial G2 arrest observed
was the result of inadequate levels of Vpr expression, we
transfected 293T cells with an HA-tagged wild-type vpr
construct that was previously shown to induce G2 arrest
data not shown). Immunoblotting was used to detect Vpr
xpression in the transfected cells. As shown in Fig. 4, in
CI-HA-VPR-transfected cell lysate, a 14-kDa Vpr-size
ssion. A representative experiment is shown here. (A) High-efficiency
cloned vpr genes and the same backbone vector expressing GFP. At
expression. Untransfected cells are shown in the thin line, and a
of cells in the transfected sample express GFP above the background
mically arrested at G2 by nicodazol. DNA content was determined by
by dividing the percentage of cells in G2 1 M by that in G1 1 G0. (C)
th pCI-HXB2 expressing a nonfunctional vpr. (E) 293T cells transfected
I-VPR, a representative patient vpr from patient 13.
FIG. 3. Comparison of relative cell cycle arrest (in relation to func-
tional Vpr-NL4-3) in cells transfected with functional (NL4-3), nonfunc-
tional (HXB2) vpr gene, vector pCI alone, or the vpr genes from patient
solates. Standard deviations are shown in error bars.progre
taining
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230 SHEN ET AL.band was detected using an anti-HA antibody. The band
is absent in cells transfected with vector alone or in
untransfected cells. These results demonstrate that
readily detectable amounts of Vpr are made in trans-
fected cells and in this system induce a modest but
significant level of G2 arrest. It was previously reported
that Vpr expression levels did not directly correlate with
the amount of G2 arrest in transfected cells and that a
arely detectable level of Vpr by Western blot was able to
rrest cells to a significant level (Di Marzio et al., 1995).
DISCUSSION
HIV-1 persists in a latent reservoir comprised of rest-
ng CD41 T lymphocytes that carry latent provirus, even
in patients successfully treated with HAART. These la-
tently infected resting CD41 T lymphocytes are thought
to arise from infected activated T cells that revert to a
resting G0 state. The HIV-1 accessory gene product Vpr
s known to cause G2 cell cycle arrest in host cells. In
principle, the G2 arrest function of Vpr could prevent the
ctivated T lymphocytes from reverting to memory cells
fter HIV-1 infection. Therefore, we hypothesized that the
pr genes might be mutated in the integrated proviruses
n the latently infected T lymphocytes, as is seen in
hronically infected T-cell lines. These Vpr mutations
ould give rise to altered Vpr proteins that could not
ause G2 arrest in the host cells.
To test our hypothesis, we cloned the vpr genes from
iruses isolated from latently infected resting CD41 T
ells of patients on HAART. Primary sequences were
nalyzed to identify mutations that may result in inacti-
ation of Vpr. There were no obvious inactivating muta-
ions among any of the four isolates. To extend this
nalysis, we then tested the clones functionally to deter-
ine whether their ability to arrest cells at G2 was com-
FIG. 4. Western blot analysis of Vpr expression in transfected cells.
293T cells were transfected with pCI alone or HA-tagged wild-type
(from NL4-3) vpr. The arrow points at the 14-kDa Vpr-size band present
only in the vpr-transfected cells.romised. Our studies demonstrated that the vpr genes
rom all four patient isolates were capable of inducing
rrest to levels seen in using a wild-type vpr (from
L4-3).
The vpr genes in these latent proviruses were func-
ional. Interestingly, in one of the patient isolates, there is
single amino acid deletion close to the C-terminus. As
hown in our functional assays, this single amino acid
eletion does not inactivate Vpr function. This observa-
ion suggests that there was even some selective advan-
age to preserving the reading frame of vpr.
In light of the finding that vpr genes from viruses in the
atent reservoir can induce G2 arrest, several models for
the generation of latently infected memory T cells can be
considered (Fig. 5). One model suggests that latency is
established after productive infection of activated CD41
T cells. A small fraction of productively infected CD41 T
cells survive the cytopathic effects of the virus and the
host cytolytic effector mechanisms and revert to a qui-
escent state. The absence of the requisite host transcrip-
tion factors in resting cells allows the virus to enter a
latent state of infection, in which there is minimal or no
viral gene expression, and no new virus is produced by
the cells. However, there remains the question of how
infected T cells escape the Vpr-induced G2 arrest and
proceed into a resting memory state (at G0). We consid-
ered several possibilities. First, Vpr-induced G2 arrest
ight not be complete, i.e., not all cells that express vpr
re arrested at G2. In fact, this was the case in our
unctional assay, in which the level of arrest induced by
pr expression was much smaller than that induced by
he drug nicodozal. As demonstrated by our data and
ork in other laboratories, Vpr-induced G2 arrest varies
rastically in magnitude in different systems, from 47%
Gummuluru and Emerman, 1999) to 91% (Poon et al.,
998) of the cell population in G2, but is never absolute.
Thus, it is reasonable to imagine that some infected cells
would not be arrested at G2 and could revert to the
resting memory state. A second possibility is that the
Vpr-induced G2 arrest might not be permanent. Cells
could arrest at G2 for a period of time and then proceed
hrough the cell cycle (Goh et al., 1998). In this case, cells
rrested transiently could eventually revert to G0. Either
f these possibilities would allow certain productively
nfected T cells to revert to a memory state, despite the
ell cycle arrest of Vpr.
A second model suggests that latency arises from the
nfection of a T cell during a narrow window of time, in
hich T cells are reverting to a G0 memory state (Steven-
son, 1997). In this model, the fate of all productively
infected T cells is death. However, if a cell is infected
when it is already in the process of returning to a resting
state, it may be permissive for virus entry, reverse tran-
scription, and integration, but not for activation of viral
gene expression from the LTR, resulting in the genera-
tion of a latently infected cell. In this case, Vpr would not
be expressed during the time when viral latency is es-
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231HIV-1 LATENCY NOT REQUIRING Vpr INACTIVATIONtablished and, thus, would not interfere with the forma-
tion of the latent reservoir. Although virion-associated
Vpr can induce cell cycle arrest (Poon et al., 1998), the
cell might have already exited the cell cycle to G0. There-
ore, nonfunctional Vpr would not be selected in latency.
There is a third model for the generation of latently
nfected memory T cells, which involves direct infection
f T cells in the resting memory state. In this model, viral
enes are not expressed during the establishment of
atency and the cells are not cycling. The evidence for
his model is limited. It is generally believed that, al-
hough HIV-1 isolates that utilize CCR5 can enter the
ubset of resting memory CD41 T cells that express low
levels of CCR5 (Pierson et al., 2000), integration of the
provirus does not occur as a result of a failure in nuclear
import of the preintegration complex in resting cells
(Stevenson et al., 1990). However, recent work by Unut-
az et al. (1999) demonstrates that cytokine-mediated
ignals may overcome this block and allow for the inte-
ration of the HIV-1 genome following the infection of a
esting T cell (Unutmaz et al., 1999). This opens up the
ossibility that latency may be established through direct
nfection of resting memory T cells. The finding of func-
ional vpr genes in the latent compartment of patients
reated with HAART could be consistent with any of the
odels and demonstrates that a functional vpr does not
lock the generation of latently infected memory T lym-
hocytes.
FIG. 5. Two models for the generation of latently infected memory T l
death, but a small fraction of the infected cells can revert back to mem
T cells results in cell death, whereas infection of T cells that are in th
infected memory T cells.MATERIALS AND METHODS
iral isolates
Viral isolates from the latent reservoir were obtained
rom patients successfully treated with highly active an-
iretroviral therapy (HAART) with plasma virus levels be-
ow the limit of detection (50 copies/ml). Viral isolates
ere amplified for 4 days on CD8-depleted phytohemag-
lutinin (PHA)-activated peripheral blood mononuclear
ells (PBMCs). Four different isolates from four previ-
usly characterized patients (patients 8, 11, 13, and 50;
ee Finzi et al., 1999) were studied. Each viral isolate was
erived at limiting dilution as described by Finzi et al.
1997) and represents a biological clone. Genomic DNA
rom infected cultures was then isolated using the Puren-
ene Genomic DNA purification kit (Gentra Systems,
inneapolis, MN).
loning of vpr gene from latent proviruses
A sensitive PCR amplification strategy was designed
to amplify the entire vpr ORF from the genomic DNA
derived from cultures of biological clones of the virus
from the latent compartment. Primers were designed to
anneal to regions flanking vpr (corresponding to 5512 to
5536 and 5956 to 5979 on HIV-1 HXB2) that are highly
conserved in clade B HIV-1 viruses (sense primer: 59-
GATAGACGCGTAAAGATAAAGCCACCTTTGCCTAGTG-
39; antisense primer: 59-CCTTGTCCGGCGGCCGCTTC-
ytes. Model 1: Virus infection of activated T cells usually results in cell
ls with integrated proviruses. Model 2: Virus infection of fully activated
ess of reverting back to resting state results in generation of latentlyymphoc
ory cel
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c
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232 SHEN ET AL.CTGCCATAGGAGATGCCTAAG-39). Approximately 200 ng
of genomic DNA was used in a reaction containing 1 mM
each primer, 200 mM dNTPs, 1.5 mM MgCl2, and 3.5 units
of Expand High Fidelity PCR system (Boehringer Mann-
heim GmbH, Germany). The reaction was cycled be-
tween 94°C (30 s) and 65°C (30 s) for 30 cycles. Products
were analyzed by agarose gel electrophoresis. The de-
sired fragment was gel purified (Qiagen, Valencia, CA)
and cleaved with NotI and MluI for insertion into the
multiple cloning site of the pCI vector to generate vector
pCI-VPR. The plasmid vectors were transformed into
bacteria, and the positive pCI-VPR clones were picked
and sequenced using standard cycle sequencing. The
vpr genes were also PCR amplified from vectors pNL4-3
(functional vpr) and pHXB2 (truncated vpr) using the
primers mentioned above. In addition, N-terminal hem-
agglutinin (HA)-tagged vpr were also PCR amplified from
vectors pNL4-3 and pHXB2 using a sense primer with
HA-tag sequence added to the 59 end and the antisense
primer discussed above. These PCR products were then
cloned into vector pCI. HA-tagged vpr clones were des-
ignated pCI-HA-VPR.
Transfection
293T cells were cultured in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal calf serum at
37°C and 5% CO2. Cells (4 3 10
5 in 24-well plates) were
otransfected with 2 mg of pCI-VPR and 1 mg of pCI-GFP
green fluorescent protein [GFP] cloned into multiple
loning site of pCI) using the Lipofectimine 2000 trans-
ection system (GibcoBRL, Gaithersburg, MD).
ell cycle analysis
Cells were harvested 48 h after transfection and tested
or transfection efficiency using flow cytometric analysis
f GFP expression on a FACSCAN (Becton Dickinson,
an Jose, CA). The cells were then stained with pro-
idium iodide (PI) for DNA content. The staining solution,
onsisting of 1% sodium citrate, 0.1% Triton X-100, and 50
mg/ml PI, was added to the cells, which were then
incubated on ice in the staining solution for 10 min before
analysis on a FACSCAN. Expression of GFP and PI anal-
ysis were measured sequentially because the PI staining
procedure causes leakage of GFP from the cell, resulting
in a reduction in fluorescence signal. Nontransfected
cells and cells transfected with pCI alone were used as
negative controls, and cells chemically arrested at G2 (by
ncubating with 2 mg/ml nicodazol for 24 h) were used as
a positive control.
Immunoblot analysis
Protein lysates from the transfected cells (40 mg each
lane) were separated by a precast 10–20% gradient
Tricine SDS–PAGE gel (Novex, San Diego, CA). The pro-
teins were then transferred to a polyvinylidene fluoride
(PVDF) membrane (Millipore, Bedford, MA) and blottedwith a 1:1000 dilution of an HRP-conjugated anti-HA
antibody (Boehringer Mannheim).
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